Literature DB >> 20015297

Dopamine transporter down-regulation following repeated cocaine: implications for 3,4-methylenedioxymethamphetamine-induced acute effects and long-term neurotoxicity in mice.

I Peraile1, E Torres, A Mayado, M Izco, A Lopez-Jimenez, J A Lopez-Moreno, M I Colado, E O'Shea.   

Abstract

BACKGROUND AND
PURPOSE: 3,4-Methylenedioxymethamphetamine (MDMA) and cocaine are two widely abused psychostimulant drugs targeting the dopamine transporter (DAT). DAT availability regulates dopamine neurotransmission and uptake of MDMA-derived neurotoxic metabolites. We aimed to determine the effect of cocaine pre-exposure on the acute and long-term effects of MDMA in mice. EXPERIMENTAL APPROACH: Mice received a course of cocaine (20 mg*kg(-1), x2 for 3 days) followed by MDMA (20 mg*kg(-1), x2, 3 h apart). Locomotor activity, extracellular dopamine levels and dopaminergic neurotoxicity were determined. Furthermore, following the course of cocaine, DAT density in striatal plasma membrane and endosome fractions was measured. KEY
RESULTS: Four days after the course of cocaine, challenge with MDMA attenuated the MDMA-induced striatal dopaminergic neurotoxicity. Co-administration of the protein kinase C (PKC) inhibitor NPC 15437 prevented cocaine protection. At the same time, after the course of cocaine, DAT density was reduced in the plasma membrane and increased in the endosome fraction, and this effect was prevented by NPC 15437. The course of cocaine potentiated the MDMA-induced increase in extracellular dopamine and locomotor activity, following challenge 4 days later, compared with those pretreated with saline. CONCLUSIONS AND IMPLICATIONS: Repeated cocaine treatment followed by withdrawal protected against MDMA-induced dopaminergic neurotoxicity by internalizing DAT via a mechanism which may involve PKC. Furthermore, repeated cocaine followed by withdrawal induced behavioural and neurochemical sensitization to MDMA, measures which could be indicative of increased rewarding effects of MDMA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015297      PMCID: PMC2823365          DOI: 10.1111/j.1476-5381.2009.00522.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  74 in total

Review 1.  The monoamine neurotransmitter transporters: structure, conformational changes and molecular gating.

Authors:  L Norregaard; U Gether
Journal:  Curr Opin Drug Discov Devel       Date:  2001-09

Review 2.  Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands.

Authors:  Joshua M Gulley; Nancy R Zahniser
Journal:  Eur J Pharmacol       Date:  2003-10-31       Impact factor: 4.432

Review 3.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 4.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

5.  Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Neuropsychopharmacology       Date:  2003-10       Impact factor: 7.853

6.  Isoform-selectivity of PKC inhibitors acting at the regulatory and catalytic domain of mammalian PKC-alpha, -betaI, -delta, -eta and -zeta.

Authors:  Lucília Saraiva; Paula Fresco; Eugénia Pinto; Jorge Gonçalves
Journal:  J Enzyme Inhib Med Chem       Date:  2003-12       Impact factor: 5.051

7.  Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats.

Authors:  Susan Schenk; David Gittings; Malcolm Johnstone; Evangeline Daniela
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

8.  Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats.

Authors:  Evangelene Daniela; Katie Brennan; Dave Gittings; Lincoln Hely; Susan Schenk
Journal:  Pharmacol Biochem Behav       Date:  2004-04       Impact factor: 3.533

Review 9.  Dopamine in drug abuse and addiction: results from imaging studies and treatment implications.

Authors:  N D Volkow; J S Fowler; G-J Wang; J M Swanson
Journal:  Mol Psychiatry       Date:  2004-06       Impact factor: 15.992

10.  Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters.

Authors:  Hao-Wei Shen; Yoko Hagino; Hideaki Kobayashi; Keiko Shinohara-Tanaka; Kazutaka Ikeda; Hideko Yamamoto; Toshifumi Yamamoto; Klaus-Peter Lesch; Dennis L Murphy; F Scott Hall; George R Uhl; Ichiro Sora
Journal:  Neuropsychopharmacology       Date:  2004-10       Impact factor: 7.853

View more
  7 in total

1.  Cocaine self-administration produces pharmacodynamic tolerance: differential effects on the potency of dopamine transporter blockers, releasers, and methylphenidate.

Authors:  Mark J Ferris; Erin S Calipari; Yolanda Mateo; James R Melchior; David C S Roberts; Sara R Jones
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

2.  Temporal pattern of cocaine intake determines tolerance vs sensitization of cocaine effects at the dopamine transporter.

Authors:  Erin S Calipari; Mark J Ferris; Benjamin A Zimmer; David C S Roberts; Sara R Jones
Journal:  Neuropsychopharmacology       Date:  2013-05-30       Impact factor: 7.853

3.  Effect of repeated exposure to MDMA on the function of the 5-HT transporter as assessed by synaptosomal 5-HT uptake.

Authors:  Courtney Huff; Nirmal Bhide; Allen Schroering; Bryan K Yamamoto; Gary A Gudelsky
Journal:  Brain Res Bull       Date:  2013-01-12       Impact factor: 4.077

4.  Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: implications for the pathogenesis of free radical-induced neurodegenerative disorders.

Authors:  Ines Peraile; Noelia Granado; Elisa Torres; M Dolores Gutiérrez-López; Rosario Moratalla; M Isabel Colado; Esther O'Shea
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

Review 5.  Gene expression in the addicted brain.

Authors:  Zhifeng Zhou; Mary-Anne Enoch; David Goldman
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

Review 6.  Drugs of abuse and blood-brain barrier endothelial dysfunction: A focus on the role of oxidative stress.

Authors:  Ravi K Sajja; Shafiqur Rahman; Luca Cucullo
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-17       Impact factor: 6.200

Review 7.  The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.

Authors:  Thomas Steinkellner; Michael Freissmuth; Harald H Sitte; Therese Montgomery
Journal:  Biol Chem       Date:  2011-01       Impact factor: 3.915

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.